Cerebral malaria (CM) is a complex parasitic disease caused by Plasmodium sp. Failure to establish an appropriate balance between pro-and anti-inflammatory immune responses is believed to contribute to the development of cerebral pathology. Using the blood-stage PbA (Plasmodium berghei ANKA) model of infection, we show here that administration of the pro-Th2 cytokine, IL-33, prevents the development of experimental cerebral malaria (ECM) in C57BL/6 mice and reduces the production of inflammatory mediators IFN-γ, IL-12 and TNF-α. IL-33 drives the expansion of type-2 innate lymphoid cells (ILC2) that produce Type-2 cytokines (IL-4, IL-5 and IL-13), leading to the polarization of the anti-inflammatory M2 macrophages, which in turn expand Foxp3 regulatory T cells (Tregs). PbA-infected mice adoptively transferred with ILC2 have elevated frequency of M2 and Tregs and are protected from ECM. Importantly, IL-33-treated mice deleted of Tregs (DEREG mice) are no longer able to resist ECM. Our data therefore provide evidence that IL-33 can prevent the development of ECM by orchestrating a protective immune response via ILC2, M2 macrophages and Tregs.
Author Summary
Cerebral malaria (CM) caused by the parasite Plasmodium sp. is a fatal disease, especially in children. Currently there is no effective treatment. We report here our investigation on the role of a recently discovered cytokine, IL-33, in treating experimental cerebral malaria (ECM) in the susceptible C57BL/6 mice. IL-33 protects the mice against ECM. The protection is accompanied by a reduction of Th1 response and the enhancement of type 2 cytokine response. We also found that IL-33 mediates its protective effect by inducing a population of type 2 innate lymphoid cells (ILC2), which then polarize macrophages to
Introduction
Malaria remains a major health problem for humans infected with Plasmodium species. Cerebral malaria (CM) is a severe and potentially fatal neurological manifestation of infection and accounts for approximately one million deaths annually of children in sub-Saharan Africa alone [1] . CM is characterized by a strong Th1 immune response, with a robust and uncontrolled production of proinflammatory cytokines (IFN-γ and TNF-α) and chemokines (IP-10/CXCL10, KC/CXCL1 and MCP-1/CCL2) [2, 3] that contribute to vascular leakage and sequestration of parasitized red blood cells (pRBCs) and leukocytes within the brain blood vessels [4, 5] . In malaria, the balance between pro-and anti-inflammatory cytokines is critical in determining the outcome of infection, and recent evidences suggest that helminth co-infection may dampen immunopathological responses to malaria parasite by inducing a protective type-2 response [6, 7] . Studies using murine models of malaria have established that genetic background of the host affects the development and outcome of ECM. Infection of C57BL/6 mice, which present a Th1-biased phenotype, with the rodent parasite Plasmodium berghei ANKA (PbA) induces a fatal cerebral disease characterized by neurological disorders including paralysia, convulsion and coma. In contrast, BALB/c mice, that present a Th2-biased phenotype, do not develop neurological complications and die at later stages from high parasitemia and anaemia [8, 9] .
IL-33, the latest member of the IL-1 cytokine family [10] , plays an important role in Th2-associated immune responses [11, 12] . IL-33 has been linked to a number of inflammatory disorders including allergic asthma, rheumatoid arthritis, allergic rhinitis and ulcerative colitis [13] . IL-33 binds to a heterodimer receptor composed of ST2 (IL-33R) and IL-1R accessory protein, leading to the production of IL-4, IL-5, IL-10 and IL-13 from mast cells, eosinophils, Th2 lymphocytes and the newly discovered population of type 2 innate lymphoid cells (ILC2) [12] . In vitro, IL-33 has also been shown to synergize with IL-4 to drive the polarization of alternatively-activated macrophages (M2) [14] , that secrete high levels of IL-10 and TGF-β. We hypothesized that IL-33 could divert the deleterious Th1-immune response during infection and therefore protects mice from ECM.
Results reported here demonstrate that PbA-infected C57BL/6 mice treated with recombinant IL-33 presented no signs of neurological pathology associated with CM and had reduced production of pro-inflammatory cytokines and chemokines. This IL-33-protective effect was mediated by the activation of ILC2 that produced type 2 cytokines which in turn polarized anti-inflammatory M2 macrophages. Furthermore, M2 macrophages expanded Tregs, the depletion of which abrogated the protective effect of IL-33. We therefore present a previously unrecognised role of IL-33 in ECM, and provide evidence that induction of type 2 immunity by an exogenous cytokine treatment was sufficient to down-regulate the inflammatory Th1 response and ECM induced by PbA.
Results

IL-33 treatment protects mice from cerebral malaria induced by PbA
To determine whether IL-33 could modulate malaria pathogenesis, we first infected C57BL/6 mice with Plasmodium berghei ANKA (PbA) parasites (10 4 parasitized red blood cells, pRBC) and treated the mice with recombinant murine IL-33 (0.2 mg/mouse/day, intraperitoneally) starting from day 0. Body weight loss, parasitemia, clinical score and survival were monitored daily. PbA-infected control mice developed parasitemia, body weight loss and CM symptoms (head deviation, ataxia and paraplegia) from day 5 post infection, and all mice succumbed to CM by day 7-8 ( Fig. 1A-D) . In contrast, mice treated with IL-33 displayed reduced body weight loss, clinical score and survived up to day 20 post-infection when they were euthanised due to development of hyperparasitemia (up to 40% parasitemia) (Fig. 1D ). This indicates that IL-33 administration protects mice from ECM but not from malaria-induced hyperparasitemia and death. Similar results were obtained when the IL-33 treatment began one day after infection (day +1). Similar results were also obtained with 100× higher PbA infective dose (S1A-S1B Fig.) . Adherence of parasited red blood cells (pRBC) to the vascular endothelium of organs plays a key role in the pathogenesis of Plasmodium species allowing the parasite to escape clearance in the spleen [15] . In vivo imaging using luciferase-expressing PbA confirmed that the parasite biomass was significantly reduced in IL-33-treated mice indicating that the reduction in blood parasitemia was not due to an increase of parasite sequestration in the peripheric organs (Fig. 1E, F) .
CM is associated with parasite sequestration into the brain microvasculature and cerebral hemorrhage that result from excessive systemic inflammation, which involves pro-inflammatory cytokine production leading to endothelial cell activation and vascular permeability [16] . Using the luciferase-expressing PbA, we found a strong increase in parasite biomass in the brain of PBS-treated mice on day 7 post-infection (Fig. 1G, H) . In contrast, IL-33-treated animals showed a significant reduction of luciferase activity in the brain, indicating diminished pRBC accumulation. Histopathological analysis of brains from PBS-treated mice showed microhemorrhages and cytoadhesion of erythrocytes and leucocytes to the brain vasculature on day 7. Mice treated with IL-33 displayed markedly fewer hemorrhages and less vessel obstruction compared to the PBS-treated mice (Fig. 1I, J) . Finally, quantitative PCR analysis showed an upregulation of Icam-1 expression in the brain tissues of PbA-infected PBS-treated mice, that was absent in IL-33-treated mice (Fig. 1K) , consistent with the reduction of cytoadhesion in IL-33-treated mice compared to the controls.
IL-33 reduces pro-inflammatory cytokine and chemokine production in PbA-infected mice
To investigate how IL-33 might interfer with the host immune response, we measured the levels of the key Th1 cytokines (IFN-γ, IL-12 and TNF-α), key Th2 cytokines (IL-4, IL-5 and IL-13), and the regulatory cytokine IL-10 in the serum at various time-points after infection with PbA. Levels of IFN-γ, IL-12 and TNF-α rose progressively to day 5 in the serum of PBStreated mice. In contrast, the levels of these cytokines were significantly reduced in IL-33-treated mice ( Fig. 2A-C) . The levels of serum IL-5 were low in the control mice but were strongly enhanced in IL-33-treated mice, (Fig. 2D) . The levels of serum IL-4 and IL-13 were barely detectable in all groups of mice. The concentrations of serum IL-10 also increased in PBS control mice but were reduced in IL-33-treated mice (Fig. 2E ). Early production of the pro-inflammatory chemokines IP-10/CXCL10, KC/CXCL1 and MCP-1/CCL2 was also reduced in the serum of IL-33-treated mice compared to PBS-control mice ( Fig. 2F-H) . We then assessed the expression of lineage-specific transcription factors in CD4 + T cells purified from the spleen of PbAinfected mice. The Th1-specific transcription factor Tbet peaked at day 3 of infection in PBS control mice but was reduced on day 3 and unchanged on day 5 in IL-33-treated mice compared to PBS-treated mice (Fig. 2I ). IL-33 did not affect Gata3 expression in purified CD4 + T cells (Fig. 2J ), suggesting that Th2 cells are unlikely involved in IL-33-mediated protection. T cell-derived Granzyme B (GrmB) is known to drive cytotoxic T cell-mediated cerebral pathology [17] . We therefore determined GrmB expression in splenic CD8 + and CD4 + T cells.
Percentage and frequency of GrmB + CD8 + and GrmB + CD4 + T cells in PbA-infected mice was markedly increased compared to non-infected mice (Fig. 2K, L) . Granzyme B positive CD8 + and CD4 + T cells were significantly reduced in percentage and number in IL-33-treated mice compared to PBS-treated control mice (Fig. 2K, L) . Together, our results suggest that IL-33-mediated protection against ECM is likely associated with reduction in the early proinflammatory type-1 response. IL-33 induces ILC2 expansion and type 2 cytokine production in PbA-infected mice Recently, IL-33 has been found to directly induce ILC2 expansion and cytokine production in vitro and in vivo [18] [19] [20] .We therefore analysed the effect of IL-33 on ILC2 in the ECM model. The frequency and number of ILC2 in the spleen of non-infected (NI) or PbA-infected mice after treatment with PBS or IL-33 were analysed by FACS. A small but consistent percentage of lineage negative CD45 + ST2 + ICOS + cells, corresponding to ILC2 [21] , was found in the spleen of NI mice in the absence of IL-33-treatment. However IL-33-treatment significantly increased the percentage and number of ILC2 in the spleen in NI and PbA-infected mice compared to PBS-treated mice (Fig. 3A-C ). These cells were negative for lineage markers (CD4, CD11b, CD11c, NK1.1, CD3e, Ter119, FcεRI, Siglec F, Gr1, CD49b, CD5, F4/80) and positive for the innate lymphoid cell markers CD127, CD44, Sca-1, IL-1R1 and CD25 (S1C-S1D Fig.) . The proportion of Ki67 + cells among splenic ILC2 was higher in IL-33-treated mice, suggesting that at least some of these cells proliferated in situ (Fig. 3D ). Intracellular staining revealed that ILC2 from IL-33-treated mice, but not from PBS-treated mice, expressed substantial levels of IL-4, IL-5 and IL-13 after ex vivo PMA-ionomycin stimulation (Fig. 3E-F To investigate the potential role of ILC2 in IL-33-driven protection from CM, we sorted ILC2 and adoptively transferred them into naïve WT mice. One day after ILC2 transfer, mice were infected with PbA and monitored daily for parasitemia, body weight loss and neurological symptoms. Two injections of IL-33 (0.2 mg/mouse, i.p.) were given to the recipient mice 30 min and 24 h after cell transfer. An earlier study has shown that the provision of IL-33 boosts the survival and cytokine production of the transferred ILC2 cells [22] . A control group infected with PbA and similarly treated with IL-33 confirmed that IL-33 at this dose and schedule of treatment was suboptimal and not protective (Fig. 3G, H ). While the two control groups developed severe body weight loss and succumbed to CM by day 7, all the recipient mice given ILC2 exhibited limited clinical disease and survived beyond day 14 ( Fig. 3G, H ). The parasitemia of ILC2-transferred mice was reduced within the first week of infection compared to PbA control group (Fig. 3I ). Mice that received only 2 injections of IL-33, exhibited a slight reduction of parasitemia but nevertheless succumbed to CM by day 7. Histopathology analysis of the brain on day 7 revealed a significant reduction of microhemorrhages and vessel obstruction in the ILC2 recipients compared to the control mice ( 
IL-33 polarizes M2 macrophages
We then investigated the mechanism by which ILC2 protects mice against ECM. Macrophages can be divided into specific subsets according to their polarization environment, phenotype, and function. M1 (classically-activated macrophages) typically produce pro-inflammatory cytokines, including TNF-α and IL-12, whereas M2 (alternatively-activated macrophages) have been implicated in immune regulation, phagocytosis, and tissue remodeling [23, 24] . As M2 macrophages are polarized by IL-4 and IL-13, and that these cytokines are produced by ILC2, we therefore assessed the profile of macrophage polarization in mice infected with PbA with or without IL-33 treatment.
The percentage and number of CD11b + F4/80 + CD11c − cells in the spleen of mice administered with IL-33 were significantly elevated compared to that treated with PBS ( Fig. 4A-C) . Expansion of CD11b + F4/80 + CD11c − cells was accompanied by increased expression of the key M2 marker (CD206, mannose receptor) and the reduction of the M1 markers (CD86, MHC-II and CD40) on macrophages recovered from IL-33-treated mice compared to that of the PBS control mice ( Fig. 4D and S3A Fig.) . The expression of other M2 markers (Arginase-1, Ym1/chitinase 3-like 3 and Fizz1/resistin-like α) were also elevated in the spleen whereas the expression of the key M1 marker, Nos2, was reduced in IL-33-treated mice compared to that of the PBS control mice (Fig. 4E) . Interestingly, mRNA expression of heme oxygenase-1 (Hmox-1), an enzyme that converts heme into carbon monoxide, was significantly increased in the spleen of IL-33-treated mice compared to PBS-control mice (Fig. 4E ). QPCR analysis on sorted CD11b + F4/80 + CD11c − cells confirmed that splenic macrophages from IL-33-treated mice, but not from PBS-treated mice, exhibited an M2-polarization status (S3B Fig.) . Overall, our data indicate that IL-33 increases macrophage number in the spleen and promotes their polarization towards M2 phenotype. 
ILC2 promote M2 macrophage polarization
Since IL-33 alone is not sufficient to fully differenciate M2 macrophages [14] , we investigated the potential role of ILC2 in M2 polarization in vitro. Purified ILC2 were co-cultured in a transwell culture with bone marrow-derived macrophages (BMDM) in culture medium alone (M0) or supplemented with IL-4 (M2-polarizing conditions). After 24 h, BMDM were harvested and analysed by qPCR for M2 markers. Under the M0 conditions, BMDM alone did not expressed detectable M2 markers. However, when co-cultured with ILC2, a low level of Arginase-1, Ym1 and Fizz1 RNA became detectable (Fig. 5A) . Under the M2-polarizing conditions, these markers were clearly detected and markedly enhanced by the presence of ILC2 (Fig. 5A) . Functionally, the polarized M2 macrophages displayed enhanced capability to uptake dextran-FITC or pRBC compared to unpolarized macrophages (S3C-S3D Fig.) .
Since ILC2 proliferation and cytokine production are IL-7-and IL-33-dependent [25] , we determined the effect of activated-ILC2 on BMDM. To avoid any direct effect of IL-33 on BMDM, we used ST2-deficient BMDM. When cultured alone, ST2-deficient BMDM did not express any M2 markers even when IL-33 or IL-33 + IL-7 were added to the culture. In the presence of ILC2, the expression of Arginase-1 and Ym1 in the ST2-deficient BMDM was increased, and the expression of these markers were further enhanced by the addition of IL-33 alone or in combination with IL-7 (Fig. 5B) , suggesting that activated-ILC2 can produce cytokines involved in M2 polarization. The level of Fizz1 expression was high in the presence of ILC2 alone and was reduced in the presence of IL-33/IL-7. The reason of this reduction is not clear but could be due to over-stimulation of Fizz1 expression. We then analysed the production of Th2 cytokines by ILC2 in vitro. ILC2 alone (without BMDM) were able to produce low levels of IL-4, IL-5 and IL-13 in the culture supernatants. This production was markedly increased after stimulation by IL-33 and IL-7 (Fig. 5C ). Flow cytometry analysis of ILC2 confirmed that ILC2 in the culture produced IL-4 and IL-13 and the production was further enhanced by the presence of IL-33 + IL-7 (Fig. 5D, E) . The polarized M2 did not produce detectable amount of IL-33.
We next investigated the role of ILC2 in the polarization of M2 in vivo. Sorted ILC2 were adoptively transferred to naïve C57BL/6 mice which were infected with PbA and treated with suboptimal doses of IL-33, as described in Fig. 3F . The protected ILC2 recipients had increased expression of Arginase-1, Ym1 and Fizz1 in their spleen cells (Fig. 5F ), indicating that ILC2 are involved in M2 polarization in vivo. Together, our data showed that IL-33-induced ILC2 can effectively drive M2 polarization in vitro and in vivo.
The role of ILC2, M2 and Tregs in IL-33-mediated protection against ECM
Previous studies have implicated Tregs to limit disease and immunopathology in the PbAinduced models of ECM [26] [27] [28] and IL-33 has been shown to induce Tregs in vivo [20, [29] [30] [31] . We therefore explored the impact of IL-33, ILC2 and M2 macrophages on Tregs in the ECM model. First, we noted that the level of Foxp3 message in sorted splenic CD4 + T cells was increased in IL-33-treated mice during PbA-infection compared to PBS-treated mice. The percentage and total number of Foxp3 + splenic CD4 + T cells in the mice infected with PbA were significantly increased by the treatment with IL-33 ( Fig. 6A-B) . We then determined the effect of adoptively transferred ILC2 in the induction of Tregs in vivo (as described in Fig. 3F ). Suboptimal doses of IL-33 led to increased frequency of Foxp3 + cells among splenic CD4 + suggesting that IL-33 alone could induce Treg polarization which was however not sufficient to protect the mice from ECM (see Survival curve and Clinical Score in Fig. 3F ). However, the spleens of IL-33-treated PbA-infected mice given ILC2 contained significantly higher frequency of Foxp3 + among CD4 + T cells compared to those not given ILC2 (Fig. 6C-D (Fig. 6F) .
We then investigated whether the Treg population was involved in IL-33-mediated protection from ECM. For this purpose, we used DEREG mice, in which administration of diphtheria toxin (DT) leads to specific-depletion of Tregs due to expression of DT receptor-enhanced Gfp under the control of the Foxp3 promoter [32] . DEREG mice were infected with PbA and treated daily with PBS or IL-33 from the start of infection. DT was administered intraperitoneally every second day from day 1. Treg depletion in IL-33-treated DEREG mice was confirmed in the peripheral blood by flow cytometry (Fig. 7A) . As previously reported [33] , Treg depletion in PBS-treated DEREG mice has no effect on the parasitemia and survival. PbA-infected DEREG mice treated with PBS died on day 7 with severe ECM (Fig. 7B, C) . IL-33-treated infected DEREG mice did not develop CM and died at later stages from hyperparasitemia. In contrast, IL-33-treated PbA-infected DEREG mice that received DT developed cerebral disease and died by day 7. IFN-γ and Granzyme B production by splenic CD8 + T cells, which were significantly reduced in the IL-33-treated mice, was partly reversed in IL-33-treated mice after DT administration ( Fig. 7D-E ). In addition, serum levels of IFN-γ and IL-12, which were markedly reduced in IL-33-treated mice, were also restored when Tregs were depleted (Fig. 7F ).
Together these results indicate that IL-33 induces ILC2 which in turn polarize M2 macrophages. M2 can expand Tregs which mediate the suppression of the Th1 response, which is critical to ECM pathogenesis (Fig. 8) .
Discussion
Data reported here reveal a previously unrecognised role of IL-33 in the protection against cerebral malaria by reducing pro-inflammatory cytokines and chemokines production and inhibiting vascular sequestration of infected erythrocytes and inflammatory cells in the brain. Furthermore, we provide a plausible mechanistic pathway by which IL-33 induces the expansion of ILC2 which in turn promote the polarization of M2 macrophages and Tregs that are critical for the protection against ECM.
ILC2 have emerged as key players in experimental and clinical diseases [34] . They expand strongly in vivo in response to IL-25 and IL-33, and represent the predominant early source of IL-5 and IL-13 during allergic inflammation and worm infection [25, 35] . In PbA-infected mice, exogenous IL-33 induces a robust expansion and mobilization of ILC2 which have the potential to produce IL-4, IL-5 and IL-13. Adoptive transfer of ILC2 markedly ameliorated ECM. IL-33 administration following ILC transfer was necessary to induce the protection, likely because ILC2 require IL-33 stimulation to expand and produce sufficient amount of type 2 cytokines [22] . However, the possibility that IL-33 may also act on other cell types that participate in the protection against ECM cannot be excluded. In vitro, we confirmed that ILC2 can polarize BMDM into M2 macrophages in a cell-cell contact independant manner. IL-33 to Hprt1). (B) ST2-deficient BMDM were co-cultured in transwell plates as above with WT ILC2 in the presence of IL-33 alone or in combination with IL-7. After 48 h, BMDM were collected and assayed for the expression of M2 markers by qPCR (relative to Hprt1). Type 2 cytokines in the supernatants of ILC2 cultured in the presence of IL-33 or IL-33 + IL-7 were determined by ELISA (C), or by FACS (D, E). Data are mean AE SEM (n = 3 per group), representative of two independent experiments, *P<0.05, **P<0.01, ***P<0.001 by two-tailed ANOVA. (F) ILC2 sorted from mice pre-treated with IL-33 were adoptively transferred (2×10 6 cells, i.v., on day −1) into naïve C57BL/6 mice which were infected with PbA (10 4 pRBCs, i.v., on day 0). The recipients, were given 2 injections of IL-33 (0.2 μg, i.p.) 30 min and 24 h after cell transfer. Expression of Arg-1, Ym1 and Fizz1 mRNA in the spleen was measured by qPCR (relative to Hprt1) on day 7. Data are mean AE SEM (n = 5 per group) *P<0.05, **P<0.01, ***P<0.001 by two-tailed ANOVA.
doi:10.1371/journal.ppat.1004607.g005
IL-33 Protects from ECM
increased production of IL-4 and IL-13 by ILC2, which can synergize to polarize M2 macrophages [14, 36] . This is supported by our data showing that adoptively transferred ILC2 can collaborate with IL-33 to polarize M2 in vivo.
M2 macrophages exhibit potent anti-inflammatory properties and play important roles in parasite clearance, tissue repair and remodeling [37] . One of the proposed mechanism for the immunomodulatory role of M2 macrophages is the competition between Arginase-1 (expressed by M2) and iNOS (expressed by M1) for the subtrate L-Arginine [37] . Another mechanism is the production of carbon monoxide (CO) by heme-oxygenase-1 (HO-1), an enzyme which has been shown to be preferentially expressed in CD206 + M2 macrophages [38] . HO-1 
catalyzes the degradation of heme into biliverdin, iron and CO [39] . Here, we found that IL-33-treated mice expressed higher levels of HO-1 in the spleen. Free heme release during Plasmodium spp. infection contributes to blood brain barrier disruption and ECM pathogenesis [40] . CO production by HO-1 has been shown to suppress PbA-induced ECM by inhibiting blood brain barrier disruption, reducing adhesion molecule expression in the brain microvasculature and CD8 + T cell sequestration in the brain [40] . The role of IL-33 in the induction of CO via HO-1 merits further investigation. Tregs expansion by IL-2/anti-IL-2 complexes in vivo has been implicated to protect mice against T cell-mediated immune pathology in PbA-induced ECM [28] , although direct evidence for a role of Tregs in ECM remains elusive. We and others have shown earlier that IL-33 administration leads to Treg induction [20, [29] [30] [31] 41] . Here, we provide data supporting that IL-33-mediated induction of Tregs in PbA-infected mice involves the activity of ILC2 and M2 macrophages. We also show that M2 expand natural Tregs and inducible Tregs in vitro. Importantly, Tregs depletion abrogated the protective effect of IL-33 in ECM by reducing the Th1 cell response. These results therefore demonstrate a cascade of events leading to the protection of ECM by IL-33 (Fig. 8) . The detailed mechanism by which Tregs suppress effector T cells, the major immunopathological mediators of ECM, remains to be explored.
It is important to note that IL-33-treated mice produced minimal amount of IL-10 during PbA-infection (Fig. 2E) . Furthermore, administration of anti-IL-10 monoclonal antibody in IL-33-treated mice did not affect the protection conferred by IL-33 (S4A-S4B Fig.) . Therefore, 
it is unlikely that M2-or Tregs-produced-IL-10 participates to ECM protection by IL-33. This is consistent with an earlier report which shows CTLA4-dependent but IL-10-independent protection against ECM [28] .
IL-33-treated mice, though consistently showed significant reduction in parasitemia at the early stage of infection (day 5-7) compared to untreated mice, were unable to clear the parasite and eventually died at later stage from hyperparasitemia. IL-33-mediated protection was achieved when the cytokine was given relatively early after infection and delaying treatment by 48 h failed to control the disease. This observation suggests a fine temporal interplay between the protective T cell response against the parasite and the anti-inflammatory response during PbA infection. Spleen is a key site for removal of pRBC during malaria through production of reactive oxygen species and phagocytosis by activated macrophages [42] . Moreover, it has been shown that Flt3L-induced CD11b int F4/80 + red pulp macrophages, which ressemble the macrophages induced by IL-33, displayed higher phagocytic activity and contributed to parasite clearance in PbA-infected mice [43] . Here, we observed that polarized M2 macrophages showed enhanced capacity in dextran-FITC or pRBC uptake compared to unpolarized macrophages (S3C-S3D Fig.) . Therefore, the initial reduced parasitemia observed in our model could be explained by local activation and proliferation of red pulp macrophages, which might contribute to the parasite killing. Although it is possible that the low parasitemia contributed to IL-33-mediated protection by reducing PbA antigenic stimulation, it is unlikely an influential mechanism since we found that IL-33 treatment was still equally protective in mice infected with a 100× higher dose of pRBC which displayed a parasitemia > 5% (S1A-S1B Fig.) . IL-33 can directly stimulate eosinophil differentiation and survival [44] . Eosinophil granules contain cytotoxic, highly basic proteins, including the eosinophilic cationic protein that has been shown to inhibit P. falciparum in culture [45] . In our model, although the percentage and number of splenic eosinophils were augmented by 6 folds in IL-33-treated mice compared to untreated mice, eosinophil depletion using anti-Siglec-F antibody did not affect IL-33-mediated protection during PbA infection (S4C-S4G Fig.) suggesting that eosinophils are unlikely an influential mechanism in IL-33-mediated protection against ECM.
Increased number of CD4 + CD25 + Foxp3 + Tregs have been observed in humans infected with Plasmodium falciparum [27, 46, 47] . It would be of considerable interest to investigate if the observation reported here is also applicable to clinical cerebral malaria.
Materials and Methods
Animals
Female C57BL/6 mice (8-10 weeks old) were obtained from Charles River UK Ltd. ST2
−/− female mice (on the C57BL/6 genetic background) were originally provided by Dr. Andrew McKenzie (Medical Research Council Laboratory of Molecular Biology, Cambridge,U.K.) and bred in-house in a pathogen-free facility at University of Glasgow. DEREG mice (on the C57BL/6 genetic background, originally provided by Dr. Tim Sparwasser, Hannover Medical School, Germany) were bred at Transgenose Institute animal facility (UPS44 CNRS, Orleans, France). Mice under procedure were kept in polyethylene boxes with free access to food and water, and subjected to 12 h light-dark cycles. All experiments were performed in accordance with the UK Home Office guidelines and within the terms of the Project License (PPL 70/7293) granted for this work under the Animals (Scientific Procedures) Act 1986. All efforts were made to minimize the number of animals used and their suffering.
Experimental infection 
Bioluminescence imaging with IVIS
Mice infected with the transgenic PbA strain that constitutively expresses luciferase (PbA-luc, gift of Dr. AP Waters, Glasgow, UK) were imaged using an IVIS Imaging 100 system (Xenogen Corp.) Mice were injected intraperitoneally with D-luciferin (PerkinElmer, 150 mg/kg in DPBS) and anesthetized in 5% isoflurane/1L O2.min −1 atmosphere. The animals were then placed in the imaging chamber of the IVIS and anesthesia was maintained using 2% isoflurane/0.2L O 2 per mouse min −1 atmosphere. Bioluminescence (photons per second per square centimeter per steridian) was monitored over a 20 min period in previously defined regions of interest (ROI). Exposure times varied between 0.5 and 1 min, depending on signal intensity. To standardize imaging and to allow comparison between mice, the images presented in the figures were taken once luminescence plateaued. For brain bioluminescence imaging, mice were sacrificed on day 7, perfused with 20 ml ice-cold PBS and the whole brains were excised and imaged ex vivo as described previously [48] . To enhance the signal and avoid desiccation, 100 ml D-luciferin (150 mg/ml) was pipetted onto the surface of each brain 5-10 min prior to imaging.
Histology
After intracardiac perfusion with 20 ml ice-cold PBS the brain was removed, fixed with 4% neutral phosphate-buffered formalin (Merck) and embedded in paraffin. The tissue were cut into 4 mm sections and stained with hematoxylin-eosin (H&E) following standard procedures. Brain microvascular obstruction in coronal brain sections was scored by two independent observers blinded to the experimental groups using a Nikon Eclipse E400 microscope at ×400. For each brain, fields containing vessels were scored using a semi-quantitative scale (0-5) according to the severity of obstruction and the presence of microhaemorrhages: 0, no obstruction; 1, only small vessels obstructed; 2, presence of leukocytes attached to the endothelium; 3, partial obstruction, presence of leukocytes and RBC; 4, total obstruction, without haemorrhages; 5, total obstruction with haemorhages. Data are presented as the average score for each brain.
Real-time PCR
Brains and spleens were excised at indicated time-points and preserved in RNAlater (Qiagen). Bone Marrow Derived Macrophages/ILC2 co-culture and phagocytosis assay
Bone marrow cells were harvested from femur bones of C57BL/6 WT or ST2-deficient mice and cultured in petri dishes in complete medium [RPMI-1640 supplemented with 10% (vol/vol) FCS (LONZA), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin] containing 25% L929 cell-conditioning medium as a source of macrophage colony-stimulating factor (M-CSF) to differentiate into bone marrow-derived macrophages (BMDM). BMDM were harvested on day 6 and co-cultured (10 6 
ELISA and multiplex
ELISA for serum IL-13 (Ebioscience), IL-4, IL-5, CXCL1, CXCL10, CCL2 (all from R&D Systems) were performed following the manufacturer's instructions. Sensitivity of the assays was between 20 and 40 pg/ml. Concentrations of serum IFN-γ, IL-4, IL-5, IL-10, IL-12 and TNF-α were determined using a multiplex mouse cytokine assay (Invitrogen) according to the manufacturer's instructions using a Luminex 200 reader (Luminex Corp.).
Statistical analysis
Comparisons between 2 groups were performed using a 2-tailed unpaired Student's t test. Multiple groups were compared using a 2-way ANOVA followed by a Bonferroni's post-test. Values for all measurements are expressed as mean AE SEM. P<0.05 was considered statistically significant. Data are representative of at least 3 separate experiments unless otherwise stated in the legend. Statistical analysis were performed using GraphPad Prism 5.0. (GraphPad Software).
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